Puig, Lluís http://orcid.org/0000-0001-6083-0952
Fujita, Hideki
Thaçi, Diamant
Zheng, Min
Hernandez Daly, Ana Cristina
Leonardi, Craig
Lebwohl, Mark G.
Barker, Jonathan
Funding for this research was provided by:
Boehringer Ingelheim
Article History
Received: 31 May 2024
Accepted: 2 July 2024
First Online: 1 August 2024
Declarations
:
: Lluís Puig has received consultancy/speaker’s honoraria from and/or participated in clinical trials sponsored by AbbVie, Almirall, Amgen, Baxalta, Biogen, Boehringer Ingelheim, Celgene, Gebro Pharma, Janssen, JS BIOCAD, LEO Pharma, Lilly, Merck Serono, MSD, Mylan, Novartis, Pfizer, Regeneron, Roche, Sandoz, Samsung Bioepis, Sanofi and UCB. Hideki Fujita has received honoraria or fees for serving on advisory boards, as a speaker and as a consultant, as well as grants as an investigator from AbbVie, Amgen, Boehringer Ingelheim, Celgene, Chugai Pharmaceutical, Eisai, Eli Lilly, Janssen, Japan Blood Products Organization, JMEC, Kaken, Kyorin, Kyowa Kirin, LEO Pharma, Maruho, Mitsubishi Tanabe Pharma, Nihon Pharmaceutical, Novartis, Sanofi, Sun Pharma, Taiho, Torii, UCB and Ushio. Diamant Thaçi declares having attended advisory boards and/or received consultancy fees and/or receiving grants as an investigator from AbbVie, Almirall, Amgen, Beiersdorf, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly, Galapagos, Janssen-Cilag, LEO Pharma, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Samsung, Sanofi, Sun Pharmaceutical Industries and UCB. Min Zheng has received grants, consulting fees and/or speaker’s fees from AbbVie, Boehringer Ingelheim, Janssen-Cilag, LEO Pharma China, Novartis, Pfizer and Xian-Janssen. Ana Cristina Hernandez Daly is an employee of Boehringer Ingelheim. Craig Leonardi has received honoraria or fees for serving on advisory boards, as a speaker and as a consultant, as well as grants as an investigator from AbbVie, Actavis, Amgen, Boehringer Ingelheim, Celgene, Coherus, Dermira, Eli Lilly, Galderma, Janssen, Merck, Novartis, Pfizer, LEO Pharma, Sandoz, Stiefel, UCB, Vitae and Wyeth. Mark G. Lebwohl is an employee of Mount Sinai and receives research funds from: AbbVie, Amgen, Arcutis, Avotres, Boehringer Ingelheim, Cara Therapeutics, Dermavant Sciences, Eli Lilly, Incyte, Janssen Research & Development, LLC, Ortho Dermatologics, Regeneron, and UCB, Inc., and is a consultant for Aditum Bio, Almirall, AltruBio Inc., AnaptysBio, Arcutis, Inc., Arena Pharmaceuticals, Aristea Therapeutics, Avotres Therapeutics, BiomX, Brickell Biotech, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Celltrion, Corevitas, Dermavant Sciences, Evommune, Inc., Facilitation of International Dermatology Education, Forte Biosciences, Foundation for Research and Education in Dermatology, Hexima Ltd, Incyte, LEO Pharma, Meiji Seika Pharma, Mindera, Pfizer, Seanergy, Trevi, Vial, and Verrica. Jonathan Barker declares having attended advisory boards and/or received consultancy fees and/or spoken at sponsored symposia, and/or received grant funding from AbbVie, Almirall, Amgen, AnaptysBio, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer, Samsung, Sienna, Sun Pharmaceutical Industries and UCB.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.